These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 37853437)

  • 1. Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer.
    Zeng Z; Fu M; Hu Y; Wei Y; Wei X; Luo M
    Mol Cancer; 2023 Oct; 22(1):172. PubMed ID: 37853437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stem cell programs in cancer initiation, progression, and therapy resistance.
    Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
    Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer stem cells (CSCs) in cancer progression and therapy.
    Najafi M; Farhood B; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8381-8395. PubMed ID: 30417375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review.
    Dzobo K; Senthebane DA; Ganz C; Thomford NE; Wonkam A; Dandara C
    Cells; 2020 Aug; 9(8):. PubMed ID: 32823711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer stem cell (CSC) resistance drivers.
    Najafi M; Mortezaee K; Majidpoor J
    Life Sci; 2019 Oct; 234():116781. PubMed ID: 31430455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications.
    Wu HJ; Chu PY
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of microRNAs in the regulation of breast cancer stem cells.
    Liu S; Clouthier SG; Wicha MS
    J Mammary Gland Biol Neoplasia; 2012 Mar; 17(1):15-21. PubMed ID: 22331423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Stem Cells: Acquisition, Characteristics, Therapeutic Implications, Targeting Strategies and Future Prospects.
    Yadav AK; Desai NS
    Stem Cell Rev Rep; 2019 Jun; 15(3):331-355. PubMed ID: 30993589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
    Du B; Shim JS
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer stem cells.
    Yu Z; Pestell TG; Lisanti MP; Pestell RG
    Int J Biochem Cell Biol; 2012 Dec; 44(12):2144-51. PubMed ID: 22981632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
    Yan Y; Zuo X; Wei D
    Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis.
    Marquardt S; Solanki M; Spitschak A; Vera J; Pützer BM
    Semin Cancer Biol; 2018 Dec; 53():90-109. PubMed ID: 29966677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
    Navas T; Pfister TD; Colantonio S; Aziz A; Dieckman L; Saul RG; Kaczmarczyk J; Borgel S; Alcoser SY; Hollingshead MG; Lee YH; Bottaro DP; Hiltke T; Whiteley G; Takebe N; Kinders RJ; Parchment RE; Tomaszewski JE; Doroshow JH
    PLoS One; 2018; 13(6):e0199361. PubMed ID: 29928062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The bad seed: Cancer stem cells in tumor development and resistance.
    Koren E; Fuchs Y
    Drug Resist Updat; 2016 Sep; 28():1-12. PubMed ID: 27620951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.
    Keysar SB; Le PN; Miller B; Jackson BC; Eagles JR; Nieto C; Kim J; Tang B; Glogowska MJ; Morton JJ; Padilla-Just N; Gomez K; Warnock E; Reisinger J; Arcaroli JJ; Messersmith WA; Wakefield LM; Gao D; Tan AC; Serracino H; Vasiliou V; Roop DR; Wang XJ; Jimeno A
    J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27634934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.
    Geng S; Guo Y; Wang Q; Li L; Wang J
    Arch Dermatol Res; 2013 Jan; 305(1):35-47. PubMed ID: 22740085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
    Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
    Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.
    Suresh R; Ali S; Ahmad A; Philip PA; Sarkar FH
    Adv Exp Med Biol; 2016; 890():57-74. PubMed ID: 26703799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of VEGFR-2 inhibitors exerting significant anticancer activity against CD44+ and CD133+ cancer stem cells (CSCs): Reversal of TGF-β induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma.
    Modi SJ; Kulkarni VM
    Eur J Med Chem; 2020 Dec; 207():112851. PubMed ID: 33002846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing precision medicine panels for drug refractory cancers targeting cancer stemness traits.
    Warrier S; Patil M; Bhansali S; Varier L; Sethi G
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188475. PubMed ID: 33188876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.